ACADIA PHARMACEUTICALS INC 4

4 · ACADIA PHARMACEUTICALS INC · Filed Jan 16, 2015

Form 4

Period: 2015-01-15

Director

Transactions

Exercise/Conversion
Common Stock
2015-01-15$9.04/sh+10,000$90,400→ 10,000 total
Sale
Common Stock
2015-01-15$33.02/sh−27,973$923,766→ 0 total
Exercise/Conversion
Stock Option (right to buy)
2015-01-15−4,977→ 0 total
Exercise: $9.04Exp: 2016-06-12→ Common Stock (4,977 underlying)
Exercise/Conversion
Common Stock
2015-01-15$9.04/sh+4,977$44,992→ 14,977 total
Exercise/Conversion
Common Stock
2015-01-15$15.02/sh+10,000$150,200→ 24,977 total
Exercise/Conversion
Stock Option (right to buy)
2015-01-15−10,000→ 0 total
Exercise: $9.04Exp: 2016-06-12→ Common Stock (10,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2015-01-15−2,996→ 0 total
Exercise: $15.02Exp: 2017-06-14→ Common Stock (2,996 underlying)
Exercise/Conversion
Common Stock
2015-01-15$15.02/sh+2,996$45,000→ 27,973 total
Exercise/Conversion
Stock Option (right to buy)
2015-01-15−10,000→ 0 total
Exercise: $15.02Exp: 2017-06-14→ Common Stock (10,000 underlying)

Footnotes (4)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2014.
[F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.635 to $33.63 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
[F3]25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2006.
[F4]25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 15, 2007.

Documents

1 file